Cancer BiologyNeuro-OncologyPeer-reviewed
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials
Priscilla Chan, Yoshiko Nagai, Qiulian Wu…·Steve A. Kay
This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.
19 citationstop 2%